Antibody response to the messenger RNA corona virus disease 2019 vaccine in liver transplant recipients
Rujittika Mungmunpuntipantip, Viroj Wiwanitkit – 27 April 2022
Letter to the editor: Hepatitis B virus genotype: A significant risk factor in determining which patients with chronic hepatitis B virus infection should undergo surveillance for hepatocellular carcinoma: The hepatitis B Alaska study
Aashish Kumar, Deepak Rajani, Satesh Kumar – 27 April 2022
NAFLD‐related hepatocellular carcinoma: The growing challenge
Pir Ahmad Shah, Rashmee Patil, Stephen A. Harrison – 27 April 2022 – Hepatocellular carcinoma (HCC) is a common cause of cancer‐related mortality and morbidity worldwide. With the obesity pandemic, NAFLD‐related HCC is contributing to the burden of disease exponentially. Genetic predisposition and clinical risk factors for NAFLD‐related HCC have been identified. Cirrhosis is a well‐known and major risk factor for NAFLD‐related HCC.
Serum Mac‐2 binding protein level predicts the development of liver‐related events and colorectal cancer in patients with NAFLD
Yoshihiro Kamada, Takashi Nakahara, Kensuke Munekage, Hideki Fujii, Yoshiyuki Sawai, Yoshinori Doi, Masafumi Ono, Hideyuki Hyogo, Yoshio Sumida, Koichi Morishita, Tatsuya Asuka, Tsunenori Ouchida, Yasuharu Imai, Eiji Miyoshi, Japan Study Group of NAFLD – 26 April 2022 – We previously demonstrated that Mac‐2 binding protein (M2BP) is a useful biomarker for nonalcoholic fatty liver disease (NAFLD), particularly NAFLD fibrosis prediction. In the present study, we investigated the prognostic value of M2BP in patients with NAFLD.
Palliative Care and Symptom-Based Management in Decompensated Cirrhosis
AASLD develops evidence-based practice guidelines and practice guidances which are updated regularly by a multi-disciplinary panel of experts, including hepatologists, and include recommendations of preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.
CAQ Corner: Cardiovascular and pulmonary evaluation of liver transplantation candidates: What you need to know for the board exam
Manhal Izzy, Hilary M. DuBrock – 25 April 2022
Association between birth weight, preterm birth, and nonalcoholic fatty liver disease in a community‐based cohort
Coralie Amadou, Oumarou Nabi, Lawrence Serfaty, Karine Lacombe, Jérôme Boursier, Philippe Mathurin, Céline Ribet, Victor Ledinghen, Marie Zins, Marie‐Aline Charles – 25 April 2022
How did we get here?
Jorge Reyes, Evelyn Hsu – 25 April 2022
Impact of the new definition of metabolic dysfunction–associated fatty liver disease on detection of significant liver fibrosis in US adolescents
Stefano Ciardullo, Marco Carbone, Pietro Invernizzi, Gianluca Perseghin – 25 April 2022 – Recently, an expert panel proposed diagnostic criteria for metabolic dysfunction–associated fatty liver disease (MAFLD) in the pediatric population. The aim of this study was to evaluate the prevalence of MAFLD among US adolescents and to investigate whether the new MAFLD definition is able to identify individuals with more advanced liver disease.
Long‐term follow‐up of living liver donors: A single‐center experience
Robert A. Fisher – 25 April 2022